Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis

Company Overview

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $2.93 to $3.20
• 50-Day Range: $1.36 to $6.35
• 52-Week Range: $1.27 to $9.47
• Volume: 12,447 shs
• Average Volume: 70,059 shs
• Market Capitalization: $8.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Cyclerion Therapeutics Stock Analysis - MarketRank™

Cyclerion Therapeutics scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Cyclerion Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Cyclerion Therapeutics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.33% of the float of Cyclerion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cyclerion Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclerion Therapeutics has recently decreased by 28.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cyclerion Therapeutics does not currently pay a dividend.

Dividend Growth

Cyclerion Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.33% of the float of Cyclerion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cyclerion Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclerion Therapeutics has recently decreased by 28.72%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Cyclerion Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

36.10% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CYCN Stock Analysis - Frequently Asked Questions

How have CYCN shares performed this year?

Cyclerion Therapeutics' stock was trading at $3.22 at the start of the year. Since then, CYCN stock has decreased by 7.1% and is now trading at $2.99.
View the best growth stocks for 2025 here.

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced its quarterly earnings data on Tuesday, November, 9th. The company reported ($5.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($7.00) by $1.80. The firm earned $0.35 million during the quarter, compared to analysts' expectations of $3 million.

When did Cyclerion Therapeutics' stock split?

Cyclerion Therapeutics shares reverse split before market open on Tuesday, May 16th 2023. The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cyclerion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclerion Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), General Electric (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 1/21/2025
• Next Earnings (Estimated): 3/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYCN
• CUSIP: N/A
• CIK: 1755237
• Web: www.cyclerion.com
• Phone: (857) 327-8778
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,260,000.00
• Net Margins: N/A
• Pretax Margin: -2,722.68%
• Return on Equity: -55.32%
• Return on Assets: -48.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.07
• Quick Ratio: 5.07

Sales & Book Value

• Annual Sales: $1.62 million
• Price / Sales: 5.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.62 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 2,710,000
• Free Float: 1,732,000
• Market Cap: $8.10 million
• Optionable: No Data
• Beta: 1.71